Background: Estrogen is the strongest risk factor for breast cancer, especially hormone receptor positive subtypes. Anti- Müllerian hormone (AMH) can stimulate apoptosis, reduces breast tumor growth, and also has several actions in the steroid biosynthetic pathway. Therefore, there may be a correlation between AMH and breast cancer. Aims: In this study, we evaluate the correlation between AMH levels and the estrogen receptor (ER) or progesterone receptor (PR) status of breast cancer. Methods: This retrospective study was performed at two University Hospitals between August 2018 and April 2019. Serum AMH level, ER and PR status of the tumors were extracted from medical records. Results: Totally 100 premenopausal women with biopsy proven breast cancer were included in our study. AMH level was slightly higher in patients with ER positive than those with ER negative tumors, however, the difference was not significant (3.33 ± 3.15 vs 2.71± 2.06, p-value =0.69). In categorized AMH level, however, we could not find any significant differences between ER positive and negative as well as PR positive and negative patients. Conclusion: This study shows that there might be an association between serum AMH and breast cancer subtype regarding hormone receptors. We propose larger studies to be performed in order to verify this important issue further.